岁末年初，药企高管缘何密集迎人事变动？

Group 1 - Zhou Yunshu has been appointed as the president of Xiansheng Pharmaceutical, marking his return to the pharmaceutical industry after leaving Heng Rui Medicine over four years ago [1][4] - The strategic cooperation agreement between Jiangsu Provincial Tumor Hospital and Xiansheng Pharmaceutical's key laboratory indicates a significant collaboration in cancer treatment [1] - Xiansheng Pharmaceutical has shown strong growth, with a 15.14% increase in revenue to 3.585 billion yuan and a 32.2% rise in net profit to 604 million yuan in the first half of 2025 [5] Group 2 - The recent wave of executive changes in the pharmaceutical industry reflects a trend of local companies actively adjusting strategies and optimizing talent to face the globalization of innovative drugs [3][10] - High-profile executives with multinational backgrounds are joining local pharmaceutical companies, which is expected to enhance management systems and research processes [3][9] - The approval of 76 innovative drugs in 2025 and over $130 billion in licensing transactions highlight a milestone for the Chinese pharmaceutical industry, emphasizing the need for capable leadership in the evolving market [10]